Pharmaceutical companies have more reasons than ever to hone their launch readiness skills. The question is whether they possess the new product launch strategies and tools to successfully commercialise their new medicines in an often volatile and always competitive global marketplace.
As we inch warily or rush enthusiastically into another year against a backdrop of political turmoil and business uncertainty in major markets, it is time to look at the prevailing 2019 pharmaceutical industry trends and what they might mean for companies launching new medicines, negotiating market access barriers, or simply trying to do what they do better. Inevitably, the US is in the thick of the action. But there are many other important 2019 pharma trends, both national and global, that will set the pace for industry throughout what promises to be another dynamic and challenging year.
As the challenges to pharmaceutical launch strategy, market access and success, become ever more imposing, no-one will prevail by throwing money and reps at the problem as companies did in the past.
A healthy pharmaceutical industry runs on innovation. There is plenty of that left in the tank, judging by current market trends and product development pipelines. Pharma launch challenges, though, have never been tougher.